JNCE / Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug

Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma. more_horizontal

Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company. more_horizontal

Fintel reports that Tang Capital Partners has filed a 13D form with the SEC disclosing ownership of 5.30MM shares of Jounce Therapeutics Inc (JNCE). more_horizontal

Jounce Therapeutics (NASDAQ: JNCE ) stock is climbing higher on Wednesday after getting an unexpected acquisition bid from Concentra Biosciences. That more_horizontal

Jounce Therapeutics (NASDAQ: JNCE ) stock is on the rise Thursday after the company revealed merger plans with Redx Pharma . Jounce Therapeutics and R more_horizontal

Jounce has recently announced that it has sold its entire rights to immunotherapy candidate GS-1181 to Gilead for $67 million. I expect the biotech co more_horizontal

Jounce Therapeutics (NASDAQ: JNCE ) stock jumped after it sold rights to a cancer drug to Gilead Sciences (NASDAQ: GILD ). Shares were trading as high more_horizontal

Jounce Therapeutics Inc. JNCE, -6.66% shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. more_horizontal